ABM Therapeutics

Focus: ABM Therapeutics is a China-based biotech company focused on small molecule therapeutics for brain cancers, operating in oncology and neurology. The company is in early-stage development with a minimal disclosed operational footprint.

Oncology Neurology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About ABM Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow ABM Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ABM-168

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT05831995Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

Phase 1

Help build intelligence for ABM Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity in underserved oncology/neurology space with potential for significant equity upside if programs advance
Focused pipeline targeting high-unmet-need brain cancers positions the company for differentiation in a competitive market
China-based location offers access to growing biotech ecosystem and potentially lower cost structure

Watch Out For

No active job openings and minimal public hiring signal suggest limited near-term growth or uncertain operational status
All pipeline programs remain in Phase 1 with no Phase 2+ data, indicating very early validation and high technical risk
Lack of published financials, funding data, and public disclosure raises concerns about company stability and transparency

Generated by Claude from ABM Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ABM-1310

Advanced Solid Tumor

Phase 1

Clinical Trials (3)

NCT05501912A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Phase 1

NCT04190628Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Phase 1

NCT05892653A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors

Phase 1

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

4 pipeline

Marketed

Pipeline